eMedicine Specialties > Emergency Medicine > Pediatric

Pediatrics, Anaphylaxis: Follow-up

Author: Jeffrey F Linzer Sr, MD, MICP, FAAP, FACEP, Associate Professor of Pediatrics and Emergency Medicine, Emory University School of Medicine; Associate Medical Director for Business Affairs and Compliance and EMS/Pre-Hospital Care Coordinator, Department of Pediatrics, Division of Pediatric Emergency Medicine, Emory University School of Medicine; Emergency Pediatric Group, Children's Healthcare of Atlanta at Egleston; Co-Medical Director and Consulting Staff, Children's Sedation Service, Children's Healthcare of Atlanta at Egleston
Contributor Information and Disclosures

Updated: Oct 5, 2009

Follow-up

Further Inpatient Care

  • Patients with symptoms that require admission should continue to receive supportive care (eg, intravenous fluids, vasopressors, antihistamines, steroids) as indicated.

Further Outpatient Care

  • Patients with anaphylaxis should follow up with their pediatrician and be given a referral for allergy evaluation and counseling.

Inpatient & Outpatient Medications

  • All patients who had more than mild symptoms and/or required more than 4 hours of observation should be given a prescription for an auto-injector of epinephrine. Patients and families should be advised to call 911 or seek immediate medical attention after epinephrine self-administration.
  • Patients should be continued on H 1 and H 2 blockers for 3 days after resolution of symptoms. A second generation H 1 may be used as part of discharge care.
  • A 3-day course of oral steroids may be warranted.

Transfer

  • Patients who require aggressive or extensive stabilization should be admitted to an intensive care unit at a tertiary pediatric center.

Deterrence/Prevention

  • Consider discharging patients with an action plan (such as those from the American Academy of Asthma, Allergy and Immunology or Food Allergy and Anaphylaxis Network).
  • Exposure to inciting agent, if known, should be avoided.
  • When avoidance is impossible, the patient should receive prophylaxis with H 1 and H 2 antihistamines and steroids after exposure. Also, the patient should have an auto-injector of epinephrine readily available for use if severe symptoms develop.

Complications

Prognosis

  • Prognosis is good if treated early.
  • Development of shock is a poor prognostic indicator.

Patient Education

Miscellaneous

Medicolegal Pitfalls

  • Using medications other than epinephrine for initial care
  • Failure to identify and treat appropriately
  • Failure to prescribe an auto-injector of epinephrine
  • Nonreferral to an allergy-immunology specialist
 


More on Pediatrics, Anaphylaxis

Overview: Pediatrics, Anaphylaxis
Differential Diagnoses & Workup: Pediatrics, Anaphylaxis
Treatment & Medication: Pediatrics, Anaphylaxis
Follow-up: Pediatrics, Anaphylaxis
References
Further Reading
[ CLOSE WINDOW ]

References

  1. Simons EFR. Advances in H1-antihistamines. N Engl J Med. Nov 2004;351 (21):2203-17. [Medline].

  2. Ogawa Y, Grant JA. Mediators of anaphylaxis. Immunol Allergy Clin North Am. May 2007;27(2):249-60, vii. [Medline].

  3. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. Jan 3 2008;358(1):28-35. [Medline].

  4. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. Jan 8 2001;161(1):15-21. [Medline]. [Full Text].

  5. Lieberman P, Camargo CA Jr, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. Nov 2006;97(5):596-602. [Medline].

  6. Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD. Epidemiology of anaphylaxis in Olmsted County: A population-based study. J Allergy Clin Immunol. Aug 1999;104(2 Pt 1):452-6. [Medline].

  7. Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL, Weaver A, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol. Dec 2008;122(6):1161-5. [Medline].

  8. Sheikh A, Alves B. Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data. Clin Exp Allergy. Oct 2001;31(10):1571-6. [Medline].

  9. Simons FE, Peterson S, Black CD. Epinephrine dispensing patterns for an out-of-hospital population: a novel approach to studying the epidemiology of anaphylaxis. J Allergy Clin Immunol. Oct 2002;110(4):647-51. [Medline].

  10. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol. Mar 2004;113(3):536-42. [Medline].

  11. [Guideline] Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology; American College of Allergy,Asthma and Immunology and Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. Mar 2005;115(3 Suppl 2):S483-523. [Medline].

  12. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. Feb 2006;117(2):391-7. [Medline]. [Full Text].

  13. Kobrynski LJ. Anaphylaxis. Clin Ped Emerg Med. 2007;8:110-16. [Full Text].

  14. Sicherer SH, Sampson HA. Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol. Sep 2007;120(3):491-503. [Medline].

  15. Schwartz LB, Irani AM. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am. Jun 2000;14(3):641-57. [Medline].

  16. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev. Oct 8 2008;CD006312. [Medline]. [Full Text].

  17. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. Jan 1998;101(1 Pt 1):33-7. [Medline].

  18. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. Nov 2001;108(5):871-3. [Medline].

  19. [Guideline] Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy. Aug 2007;62(8):857-71. [Medline]. [Full Text].

  20. American Heart Association. Part 12: Pediatric Advanced Life Support. Circulation. 2005;112(Suppl 1):IV-167-87. [Full Text].

  21. Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. Nov 2000;36(5):462-8. [Medline].

  22. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. Sep 2005;95(3):217-26. [Medline].

  23. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. Aug 2008;63(8):1061-70. [Medline].

[ CLOSE WINDOW ]

Further Reading

AAAAI Board of Directors. Position Statement: Anaphylaxis in schools and other child-care settings. American Academy of Allergy Asthma & Immunology. Available at http://www.aaaai.org/media/resources/academy_statements/position_statements/ps34.asp. Accessed August 19, 2007.

AAAAI School Tools: Allergy & Asthma Resources for Professionals. Available at http://www.aaaai.org/professionals/school_tools.stm. Accessed April 30, 2009.

[ CLOSE WINDOW ]

Keywords

anaphylaxis, anaphylaxis symptoms, anaphylaxis in children, allergic reaction, treating anaphylaxis, anaphylaxis syndrome, bee sting, drug allergy, food allergens, food allergy, latex allergy, peanut anaphylaxis, severe allergic reaction, venomous sting/bite

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Jeffrey F Linzer Sr, MD, MICP, FAAP, FACEP, Associate Professor of Pediatrics and Emergency Medicine, Emory University School of Medicine; Associate Medical Director for Business Affairs and Compliance and EMS/Pre-Hospital Care Coordinator, Department of Pediatrics, Division of Pediatric Emergency Medicine, Emory University School of Medicine; Emergency Pediatric Group, Children's Healthcare of Atlanta at Egleston; Co-Medical Director and Consulting Staff, Children's Sedation Service, Children's Healthcare of Atlanta at Egleston
Jeffrey F Linzer Sr, MD, MICP, FAAP, FACEP is a member of the following medical societies: American Academy of Pediatrics, American College of Allergy, Asthma and Immunology, American College of Emergency Physicians, and Medical Association of Georgia
Disclosure: Nothing to disclose.

Medical Editor

Kirsten A Bechtel, MD, Associate Professor, Department of Pediatrics, Yale University School of Medicine; Attending Physician, Department of Pediatric Emergency Medicine, Yale-New Haven Children's Hospital
Kirsten A Bechtel, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Wayne Wolfram, MD, MPH, 
Wayne Wolfram, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Pediatrics, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Richard G Bachur, MD, Associate Professor of Pediatrics, Harvard Medical School; Associate Chief and Fellowship Director, Attending Physician, Division of Emergency Medicine, Children's Hospital of Boston
Richard G Bachur, MD is a member of the following medical societies: American Academy of Pediatrics, Society for Academic Emergency Medicine, and Society for Pediatric Research
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.